Nnaomedicine

1. A NEW COMPOUND BY NANO BIOTECH
FOR
Gastro Esophageal Reflux Disease(GERD)
A Discovery Made By Nanosgroup
IN USA;
* About 44% of the US adult population have heartburn at least once a month
* 14% of Americans have symptoms weekly
* 7% have symptoms daily
mewasinghsandhu@hotmail.com- 609-902-7128
www.nanosgroup.com
Meda Biotech, USA

2. Opportunity
 The global Gastro esophageal Reflux Disease
(GERD) market was worth $ 21.5 billion in 2009. It
is forecast to decline at a Compound Annual Growth
Rate (CAGR) of 8.7% for the next eight years to reach
$10.4 billion by 2017. The high projected rate of
decline is primarily attributable to the patent
expiries of all Proton Pump Inhibitors (PPIs) by the
end of the forecast period. Increase in the treatment
seeking population, the diagnosis population and
long term anti-reflux maintenance therapy are
expected to sustain the GERD market.

3. Proof of concept
 A new drug developed for GERD
 The drug releases at stomach where the environment
is acidic
 As the formulation hits the acidic conditions, it
burst out to release the active molecule which
absorbed by the tissue to east out the acid reflux
conditions
 While the drug is absorbed the local environment of
the stomach be eased out from acidic conditions too

4. COXTOIT- A Safe And Better Compound
COXTOIT
Nano-Technology for drug delivery and better absorption
IT WORKED
To ReliefEase on acid

5. COXTOIT-Chemistry- Nanotechnology
XX 2
Nattural, COXMIX
Nexium
Prilosec
Prevacid
Protonix

6. Opportunity
It is estimated that GERD affects 25%–35% of the
population. Approximately 25 million adult
Americans have acid reflux, or heartburn, on a daily
basis, and more than 60 million Americans suffer
from heartburn at least once a month.
Main parent starting material is toxic for most of the
drugs in the market and end up with toxic drug. Our
parent molecule is not toxic and our drug is not toxic
too.

7. Mechanism of protection
 Act on IL6 and IL8 for cell protection in the presence
of acid. COX 2 mechanism involvement
 Prevents inflammation and ulcer caused by acid
production
 Healing the cell damage
 Reduces acidic environment
 Result in healing the damage

8. Progress
 POC>>>>>>>>>>>>>>>>>Established
 R&D>>>>>>>>>>>>>>>>~ Completed
 Pilot scale process>>>>>>> Established
 Animal Trials>>>>>>>>>>10 dogs for 30 day
safety study
 More than 100 people have used and Benefited
 GMP production>>>>>>>> Needed
 Clinical trials>>>>>>>.>>> Needed
Investment made so for over $1M
Patent Protection

9. Established
 Raw material secured
 Multiple batches reproduction in pilot scale
established
 Safety study established (10 dogs for 30 days)
 Efficacy (off record)

10. Pilot scale production

11. Plan to market/Exit
 With sufficient fund the product will be generating
revenue in three years in some parts of the globe
 In five years the product will be in USA market
cGMP and pre-clinical in
18 months
Phase-1 clinical in 9
months
Phase-2 and FDA
submission 18months
Sale in India , Bangla
desh and Dubai
Use of Data for USA
submission
Drug is for
multiple
uses